{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:26Z","timestamp":1787950046406,"version":"build-2784847793"},"reference-count":45,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508100"],"award-info":[{"award-number":["2023YFC2508100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PKU-Baidu Fund","award":["2020BD012"],"award-info":[{"award-number":["2020BD012"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The personalised treatment demands of patients with psoriasis did not get significant attention during the pandemic lockdown. This study aimed to investigate the treatment demands of patients with psoriasis with different severities, stratified by COVID-19 pandemic conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Cross-sectional study design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Multicentre study based on a national psoriasis registry in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>A total of 22\u2009425 adult patients with psoriasis were enrolled between August 2020 and September 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary and secondary outcome measures<\/jats:title>\n                  <jats:p>The primary outcomes were patient demands for quick healing of skin lesions and improving mental health, which were collected by questionnaires. Multivariable logistic models were used to examine the impact of disease severity, as measured by Psoriasis Area and Severity Index (PASI), body surface area (BSA) and Investigator\u2019s Global Assessment (IGA), on treatment demands, as stratified by COVID-19 pandemic conditions (lockdown vs non-lockdown).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Increasing PASI score significantly increased patient demands for rapid healing of skin lesions and improving mental health during non-lockdown periods. The magnitude of both associations further increased during the COVID-19 lockdown from an OR of 1.45 (95% CI 1.27 to 1.65) to 2.19 (95% CI 1.57 to 3.05) and 2.21 (95% CI 2.03 to 2.40) to 2.82 (95% CI 2.24 to 3.55), respectively. The skin lesion healing demand was more triggered by the overall irritation level (measured by IGA, OR 1.64, 95%\u2009CI 1.35 to 1.99 during non-lockdown periods vs OR 2.70, 95%\u2009CI 1.63 to 4.49 during lockdowns), while the mental health improving demand was more triggered by lesion coverage (measured by BSA, OR 2.01, 95%\u2009CI 1.85 to 2.19 vs OR 3.27, 95%\u2009CI 2.57 to 4.15).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Psoriasis aggravation significantly increased patients\u2019 treatment demands, especially during lockdowns. The used psoriasis severity measures highlighted patients\u2019 treatment demands differently. This suggests more accessible and personalised healthcare for patients with psoriasis should be available during future pandemics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079627","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T06:06:50Z","timestamp":1708150010000},"page":"e079627","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a cross-sectional study based on a national psoriasis registry in China"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-6894","authenticated-orcid":false,"given":"Zhihui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-6702","authenticated-orcid":false,"given":"Yu","family":"Jin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, and Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-5552","authenticated-orcid":false,"given":"Wen-Qing","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, and Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China"},{"name":"Peking University - Yunnan Baiyao International Medical Research Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"key":"2025101810290833000_14.2.e079627.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025101810290833000_14.2.e079627.2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1684\/ejd.2012.1802","article-title":"Prevalence of psoriasis in China: a population-based study in six cities","volume":"22","author":"Ding","year":"2012","journal-title":"Eur J Dermatol"},{"key":"2025101810290833000_14.2.e079627.3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025101810290833000_14.2.e079627.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"2025101810290833000_14.2.e079627.5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamadermatol.2019.0315","article-title":"Association of psoriasis with mental health disorders in South Korea","volume":"155","author":"Bang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025101810290833000_14.2.e079627.6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.530"},{"key":"2025101810290833000_14.2.e079627.7","doi-asserted-by":"crossref","first-page":"115078","DOI":"10.1016\/j.psychres.2023.115078","article-title":"Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019","volume":"321","author":"Liu","year":"2023","journal-title":"Psychiatry Res"},{"key":"2025101810290833000_14.2.e079627.8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1684\/ejd.2021.4146","article-title":"Psoriasis and addiction: assessing mental health based on a cross-sectional study in Germany","volume":"31","author":"Schielein","year":"2021","journal-title":"Eur J Dermatol"},{"key":"2025101810290833000_14.2.e079627.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259852","article-title":"Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic","volume":"16","author":"Chiu","year":"2021","journal-title":"PLoS ONE"},{"key":"2025101810290833000_14.2.e079627.10","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2464","article-title":"Impact of the COVID-19 pandemic on the mental health and quality of life of patients with psoriasis in tertiary care; a one-year follow-up","volume":"102","author":"Lada","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025101810290833000_14.2.e079627.11","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1111\/jdv.17450","article-title":"Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study","volume":"35","author":"Mahil","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025101810290833000_14.2.e079627.12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the medical board of the National psoriasis foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025101810290833000_14.2.e079627.13","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"2025101810290833000_14.2.e079627.14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2025101810290833000_14.2.e079627.15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","article-title":"Patient-relevant treatment goals in psoriasis","volume":"308","author":"Blome","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"2025101810290833000_14.2.e079627.16","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaa043","article-title":"Increasing access to care: telehealth during COVID-19","volume":"7","author":"Hoffman","year":"2020","journal-title":"J Law Biosci"},{"key":"2025101810290833000_14.2.e079627.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255534","article-title":"Older adults with non-communicable chronic conditions and their health care access amid COVID-19 pandemic in Bangladesh: Findings from a cross-sectional study","volume":"16","author":"Mistry","year":"2021","journal-title":"PLoS One"},{"key":"2025101810290833000_14.2.e079627.18","unstructured":"Nouri S , Khoong EC , Lyles CR , et al . Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic. NEJM Catal Innov Care Deliv 2020;1. doi:10.1056\/CAT.20.0123"},{"key":"2025101810290833000_14.2.e079627.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-10708-w","article-title":"Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study","volume":"21","author":"Singh","year":"2021","journal-title":"BMC Public Health"},{"key":"2025101810290833000_14.2.e079627.20","article-title":"Psoriasis and COVID-19: a narrative review with treatment considerations","volume":"33","author":"Elmas","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025101810290833000_14.2.e079627.21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/ced.14330","article-title":"Mental health and dermatology practice in the COVID-19 pandemic","volume":"45","author":"Lada","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2025101810290833000_14.2.e079627.22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2020.05.018","article-title":"Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey","volume":"83","author":"Kuang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025101810290833000_14.2.e079627.23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/09546634.2020.1790485","article-title":"Patient\u2019s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice","volume":"33","author":"Rodr\u00edguez-Villa Lario","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025101810290833000_14.2.e079627.24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjd.20406","article-title":"Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic","volume":"185","author":"Penso","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025101810290833000_14.2.e079627.25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/09546634.2020.1800578","article-title":"The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies","volume":"33","author":"Pirro","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025101810290833000_14.2.e079627.26","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4016"},{"key":"2025101810290833000_14.2.e079627.27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/bjd\/ljac144","article-title":"Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey","volume":"188","author":"Quirke-McFarlane","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025101810290833000_14.2.e079627.28","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14700","article-title":"Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: a single-center experience","volume":"34","author":"Polat Ekinci","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025101810290833000_14.2.e079627.29","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2147\/PPA.S263843","article-title":"Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: a web-based survey","volume":"14","author":"Wang","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2025101810290833000_14.2.e079627.30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/09546634.2021.1945655","article-title":"Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19","volume":"32","author":"van de Kerkhof","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2025101810290833000_14.2.e079627.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275293","article-title":"Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients","volume":"17","author":"Boch","year":"2022","journal-title":"PLoS One"},{"key":"2025101810290833000_14.2.e079627.32","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1097\/CM9.0000000000002563","article-title":"Updates in psoriasis diagnosis and treatment status in China: results from the National psoriasis center registry","volume":"136","author":"Yang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2025101810290833000_14.2.e079627.33","first-page":"573","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2023 edition)","volume":"56","year":"2023","journal-title":"Chin J Dermatol"},{"key":"2025101810290833000_14.2.e079627.34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/bjd.20659","article-title":"Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France","volume":"186","author":"Penso","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025101810290833000_14.2.e079627.35","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/09546634.2021.1927947","article-title":"The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey","volume":"33","author":"Kartal","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025101810290833000_14.2.e079627.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.03.490","article-title":"Assessing severity in psoriasis: correlation of different measures (PASI, BSA, And IGA) in a Canadian real-world setting","volume":"19","author":"Lane","year":"2016","journal-title":"Value in Health"},{"key":"2025101810290833000_14.2.e079627.37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","article-title":"Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"2025101810290833000_14.2.e079627.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the corrona psoriasis registry","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"key":"2025101810290833000_14.2.e079627.39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2340\/00015555-1731","article-title":"Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex","volume":"94","author":"Sampogna","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2025101810290833000_14.2.e079627.40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025101810290833000_14.2.e079627.41","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12070"},{"key":"2025101810290833000_14.2.e079627.42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ced.14314","article-title":"Management of nail psoriasis","volume":"46","author":"Thomas","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025101810290833000_14.2.e079627.43","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1346-8138.13841","article-title":"Internalized stigma in psoriasis: a multicenter study","volume":"44","author":"Alpsoy","year":"2017","journal-title":"J Dermatol"},{"key":"2025101810290833000_14.2.e079627.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07071.x"},{"key":"2025101810290833000_14.2.e079627.45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/jid.2011.427","article-title":"Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 health survey (SF-12) quality of life tool","volume":"132","author":"Grozdev","year":"2012","journal-title":"J Invest Dermatol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:29:20Z","timestamp":1760808560000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,17]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjopen-2023-079627"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079627","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}